Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The investigator aimed to evaluate the long-term (up to 10 years) follow-up of the patients who enrolled the IVUS-XPL study (Impact of IntraVascular UltraSound Guidance on the Outcomes of Xience Prime Stents in Long Lesions), which was shown the superiority of IVUS-guided stent implantation at 1 year in terms of major adverse cardiac events.
The investigator will follow-up (up to 10 years) the patients who enrolled the IVUS-XPL study (Impact of IntraVascular UltraSound Guidance on the Outcomes of Xience Prime Stents in Long Lesions).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| IVUS-guidance group | The patients who underwent drug-eluting stents implantation with IVUS guidance. | ||
| Angiography-guidance group | The patients who underwent drug-eluting stents implantation with angiography guidance without IVUS. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| The composite of major adverse cardiac events, including cardiac death, target lesion-related myocardial infarction, or ischemia-driven target lesion revascularization at 5 years and at 10 years | Major adverse cardiac events will be included the composite of cardiac death, target lesion-related myocardial infarction, or ischemia-driven target lesion revascularization. | At 5 years |
| The composite of major adverse cardiac events, including cardiac death, target lesion-related myocardial infarction, or ischemia-driven target lesion revascularization at 5 years and at 10 years | Major adverse cardiac events will be included the composite of cardiac death, target lesion-related myocardial infarction, or ischemia-driven target lesion revascularization. | At 10 years |
| Measure | Description | Time Frame |
|---|---|---|
| Cardiac death at 5 years | Secondary outcome will include both the each component of primary outcome and non-target lesion-related adverse events. | At 5 years |
| Cardiac death at 10 years | Secondary outcome will include both the each component of primary outcome and non-target lesion-related adverse events. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
The patients who enrolled in the previous IVUS-XPL study. In the IVUS-XPL trial, the patients who implatned drug-eluting stents because of ischemic heart disease (stable angina, acute coronay syndrome) were enrolled.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Myeong-Ki Hong, PhD | Contact | 82-2-2228-8460 | mkhong61@yuhs.ac |
| Name | Affiliation | Role |
|---|---|---|
| Myeong-Ki Hong, PhD | Severance Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine | Recruiting | Seoul | 120-752 | South Korea |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 31918944 | Derived | Hong SJ, Mintz GS, Ahn CM, Kim JS, Kim BK, Ko YG, Kang TS, Kang WC, Kim YH, Hur SH, Hong BK, Choi D, Kwon H, Jang Y, Hong MK; IVUS-XPL Investigators. Effect of Intravascular Ultrasound-Guided Drug-Eluting Stent Implantation: 5-Year Follow-Up of the IVUS-XPL Randomized Trial. JACC Cardiovasc Interv. 2020 Jan 13;13(1):62-71. doi: 10.1016/j.jcin.2019.09.033. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| At 10 years |
| All-cause of death at 5 years | Secondary outcome will include both the each component of primary outcome and non-target lesion-related adverse events. | At 5 years |
| All-cause of death at 10 years | Secondary outcome will include both the each component of primary outcome and non-target lesion-related adverse events. | At 10 years |
| Target-lesion related myocardial infarction at 5 years | Secondary outcome will include both the each component of primary outcome and non-target lesion-related adverse events. | At 5 years |
| Target-lesion related myocardial infarction at 10 years | Secondary outcome will include both the each component of primary outcome and non-target lesion-related adverse events. | At 10 years |
| Any myocardial infarction at 5 years | Secondary outcome will include both the each component of primary outcome and non-target lesion-related adverse events. | At 5 years |
| Any myocardial infarction at 10 years | Secondary outcome will include both the each component of primary outcome and non-target lesion-related adverse events. | At 10 years |
| Target-lesion revascularization at 5 years | Secondary outcome will include both the each component of primary outcome and non-target lesion-related adverse events. | At 5 years |
| Target-lesion revascularization at 10 years | Secondary outcome will include both the each component of primary outcome and non-target lesion-related adverse events. | At 10 years |
| Any revascularization at 5 years | Secondary outcome will include both the each component of primary outcome and non-target lesion-related adverse events. | At 5 years |
| Any revascularization at 10 years | Secondary outcome will include both the each component of primary outcome and non-target lesion-related adverse events. | At 10 years |
| Target-lesion related stent thrombosis at 5 years | Secondary outcome will include both the each component of primary outcome and non-target lesion-related adverse events. | At 5 years |
| Target-lesion related stent thrombosis at 10 years | Secondary outcome will include both the each component of primary outcome and non-target lesion-related adverse events. | At 10 years |
| Any stent thrombosis at 5 years | Secondary outcome will include both the each component of primary outcome and non-target lesion-related adverse events. | At 5 years |
| Any stent thrombosis at 10 years | Secondary outcome will include both the each component of primary outcome and non-target lesion-related adverse events. | At 10 years |
| ID | Term |
|---|---|
| D054058 | Acute Coronary Syndrome |
| ID | Term |
|---|---|
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D014652 | Vascular Diseases |
Not provided
Not provided